Table 5.
Descriptive statistics of primary outcome measured at baseline, 3-month, 9-month and 15-month after start of intervention and treatment effects as changes from baseline compared between groups
| TT | NTT | TAU | TT vs NTT | TT vs TAU | NTT vs TAU | |
|---|---|---|---|---|---|---|
| Estimated mean (SD) | Estimated mean (SD) | Estimated mean (SD) | Effectsb
(95 % CI) |
Effectsb
(95 % CI) |
Effectsc
(95 % CI) |
|
| NRS | ||||||
| Baseline | 4.55 (2.08) | 4.57 (2.08) | 4.72 (2.08) | |||
| 3 month | 2.62 (2.04) | 2.56 (2.04) | 3.97 (2.04) | −0.09 (-0.48 to 1.5) |
1.17 (0.15 to 2.19)* |
1.26 (0.27 to 2.25)* |
| 9 month | 2.85 (2.04) | 3.31 (2.04) | 3.5 (2.07) | 0.43 (-1.55 to 2.41) |
0.47 (-0.52 to 1.46) |
0.04 (-0.95 to 1.03) |
| 15 month | 3.06 (2.04) | 2.85 (2.04) | 3.6 (2.07) | −0.24 (-2.22 to 1.74) |
0.41 (-0.58 to 1.4) |
0.65 (-0.34 to 1.64) |
| NDI | ||||||
| Baseline | 21.84 (10.18) | 24.39 (10.18) | 24.18 (10.05) | |||
| 3 month | 14.62 (9.85) | 14.39 (9.96) | 21.74 (9.93) | −2.78 (-6.85 to 1.29) |
4.78 (0.67 to 8.89)* |
7.56 (3.49 to 11.63)*** |
| 9 month | 14.84 (9.85) | 16.61 (9.96) | 19.65 (9.93) | −0.78 (-4.87 to 3.31) |
2.47 (-1.64 to 6.58) |
3.25 (-0.82 to 7.32) |
| 15 month | 15.20 (9.85) | 13.80 (9.96) | 17.99 (9.94) | −3.95 (-8.02 to 0.12) |
0.45 (-3.64 to 4.54) |
4.40 (0.35 to 8.45)* |
TT tailored treatment, NTT non-tailored treatment, TAU treatment as usual group, vs versus, SD standard deviation, CI confidence interval, NRS Average pain intensity last week (0-10), NDI neck disability index (0-100); b Positive values of effects favor the tailored group; c Positive values of effects favor the non-tailored group; * comparison is significant at the 0.05 level. ** comparison is significant at the 0.01 level. *** comparison is significant at the 0.001 level